Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Belinda Presley

Nurse Practitioner, Family Bartlett, TN Nurse Practitioner

NPI 1639114671 CMS profile 10513315

2996 Kate Bond Rd, Ste 413, Bartlett, TN 38133

Open in the dashboard

General payments

$33,446

484 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Belinda Presley of Bartlett, TN is reported in the CMS Open Payments database as having received $33,446 across 484 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,355 100
2024 General $1,447 74
2023 General $1,328 76
2022 General $4,217 87
2021 General $24,098 147

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Belinda Presley
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Belinda Presley were reported at $2,355. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Belinda Presley Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $24,098 $124 $35–$379 $132
2022 $4,217 $141 $44–$430 $149
2023 $1,328 $154 $49–$476 $160
2024 $1,447 $165 $51–$504 $164
2025 $2,355 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Dexcom, Inc. $19,524 66 payments
  2. AstraZeneca Pharmaceuticals LP $6,495 25 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,289 62 payments
  4. Lilly USA, LLC $1,043 61 payments
  5. Novo Nordisk Inc $989 66 payments
  6. Corcept Therapeutics $850 38 payments
  7. Insulet Corporation $377 21 payments
  8. Xeris Pharmaceuticals, Inc. $369 22 payments
  9. Mannkind Corporation $332 22 payments
  10. Beta Bionics, Inc. $254 5 payments
  11. Other $1,924 96 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,410 22 payments
  2. Food and Beverage $8,913 454 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $1,350 2 payments
  4. Travel and Lodging $772 6 payments
Products named General payments · program years 2021–2025
  1. DEXCOM G6 TRANSMITTER Endocrinology $17,058 28 payments
  2. FARXIGA $6,355 23 payments
  3. Dexcom G6 Transmitter Endocrinology $2,466 38 payments
  4. Korlym $850 38 payments
  5. TRADJENTA $816 45 payments
  6. Ozempic $743 49 payments
  7. JARDIANCE $700 34 payments
  8. SYNJARDY $653 35 payments
  9. MOUNJARO $610 35 payments
  10. RYBELSUS $500 39 payments
  11. Other $6,147 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

4,209

Median for Nurse Practitioner: 389

Drug cost

$1,480,389

Median for Nurse Practitioner: $21,885

Branded share of claims

49.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 280 $329,082
Mounjaro Tirzepatide Brand 218 $255,942
Jardiance Empagliflozin Brand 301 $255,758
Tresiba Flextouch U-200 Insulin Degludec Brand 76 $82,498
Tresiba Flextouch U-100 Insulin Degludec Brand 124 $81,946
Synjardy Empagliflozin/Metformin Hcl Brand 92 $65,136
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 59 $64,272
Farxiga Dapagliflozin Propanediol Brand 54 $44,838
Trulicity Dulaglutide Brand 26 $42,256
Fiasp Flextouch Insulin Aspart (Niacinamide) Brand 37 $28,371

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$76,209

Of which drugs: $61

Medicare patients

297

Average age 71

Services billed

4,091

185 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 73%
Arthritis 46%
Ischemic heart disease 37%
Chronic kidney disease 32%
Depression 25%
COPD 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 35 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $197
$197 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
  • Lilly USA, LLC $52
$118 301 —
Wegovy
  • Novo Nordisk Inc $115
$115 — —
MOUNJARO
  • Lilly USA, LLC $109
$109 218 —
RYBELSUS
  • Novo Nordisk Inc $82
$82 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

484 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record